ADMA Biologics Faces Major Stock Plunge Due to Investigative Concerns Over Sales Practices

ADMA Biologics Stock Plummet Amid Serious Allegations

On March 24, 2026, ADMA Biologics, Inc. (NASDAQ: ADMA) saw its shares tumble more than 16%, prompting serious discussions in the investment community. The cause of this substantial drop can be traced back to a report released by short seller Culper Research that raised alarming questions about the company's sales practices, particularly regarding what is referred to as “channel stuffing.”

Culper's detailed analysis pointed out significant discrepancies between ADMA's reported growth figures and actual sales performance. Specifically, the report highlighted an astonishing spike in the company’s days sales outstanding (DSO), skyrocketing from 43 days at the end of the previous year to 113 days by December 31, 2025. This increase raised eyebrows and initiated inquiries into the potential implications for ADMA's financial integrity.

One of the key revelations from the Culper report was that ADMA allegedly encouraged one of its major distributors to stockpile its primary product, ASCENIV, through the offering of rebates and extended payment terms. According to the findings, this practice allowed ADMA to report revenue that it had not genuinely earned, misleading investors about the company's actual financial health and growth trajectory.

Culper asserted that if ADMA had maintained consistent payment terms without incentivizing distributors, it would have likely recorded a year-over-year revenue decline of three percent in 2025. This highlights a stark contrast between reported figures and realistic sales performance, suggesting that the only reason for the reported growth was through manipulating sales data via channel stuffing.

Following these revelations, Hagens Berman, a national shareholder rights law firm, announced its intention to investigate whether ADMA may have violated federal securities laws. Hagens Berman is encouraging affected investors to come forward and report their losses, highlighting the gravity of the situation and the potential legal ramifications for ADMA.

As an established biopharmaceutical company, ADMA Biologics focuses on developing and marketing specialty biologics designed to treat patients with immunodeficiencies, particularly through the use of ASCENIV. However, this latest investigation could tarnish its reputation and diminish investor confidence, especially if substantial evidence supporting Culper's claims emerges.

The repercussions were immediate as the market reacted to the negative news. Analysts reportedly downgraded ADMA's stock, reflecting a shift in sentiment around the company's prospects. The downturn in share price may not only affect current shareholders but could also deter potential investors from considering ADMA as a viable option, which could lead to long-term financial issues for the company.

As the investigation unfolds, it will be vital for both current and prospective investors to stay informed about developments regarding ADMA. Clarity about the financial reporting practices and any potential violations of accounting standards will be crucial in determining the future stability and credibility of ADMA Biologics, Inc. Furthermore, whistleblowers or insiders with pertinent information regarding these allegations are encouraged to step forward, increasing the potential for transparency and accountability within the company.

In conclusion, the substantial drop in ADMA Biologics' share price illustrates the volatile nature of the stock market and highlights the importance of corporate governance and ethical financial disclosures. As investors await further findings from the investigation, the unfolding events may serve as a cautionary tale regarding the potential pitfalls companies face when they prioritize short-term gains over long-term integrity.